Sanofi-Aventis Purchases $42.4 Million Worth of Regeneron Pharmaceuticals Inc (REGN)’s Stock

On Jan. 29th, Sanofi-Aventis, a European pharmaceutical group and Large Shareholder at Regeneron Pharmaceuticals Inc (NASDAQ:REGN), filed a Form 4 report at the U.S. Securities and Exchange Commission, declaring several purchases of the company’s stock. On. Jan. 27th the insider acquired – through several different transactions – more than 74,000 shares. On the following day, the pharmaceutical group bought stock yet again; this time, more than 83,000 shares. He paid prices ranging from $270.18 to $279.73 per share, inclusive. After the reported transactions –on which Sanofi spent roughly $42.4 million, the shareholder owns 15.97 million shares of the company worth more than $4.5 billion.

Ken Griffin with computers

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is, as its name clearly indicates, a $28 billion market cap integrated biopharmaceutical company that discovers, develops and manufactures medicines for the treatment of serious medical conditions. The company holds a promising product pipeline and a leading monoclonal antibody research and development platform. Trading at 41.8 times its earnings, a 30% discount versus the industry average valuation, while offering industry leading margins and returns –more than triple the industry mean values, this stock looks like a catch. In fact, most analysts consider this company´s stock to be a buy or strong buy case, and expect it to deliver above average annual EPS growth rates over the next five years (31.5% in average).

Sanofi, a healthcare company more than four times bigger than Regeneron Pharmaceuticals Inc (NASDAQ:REGN) in terms of market cap, continues to invest in this pharmaceutical company and many analysts consider that an acquisition could occur somewhere down the road. If this were to happen, other stockholders could result highly benefited.

Besides analysts and Sanofi, there are several hedge funds that also seem to like Regeneron Pharmaceuticals Inc (NASDAQ:REGN). In its last 13F form, Samuel Isaly´s Orbimed Advisors –the largest “hedgie” bull- declared an increase of 46% in its position in the stock. The fund now holds 513,100 shares, valued at approximately $ 1.46 billion. This position comprised 2.86% of Orbimed´s Q3 equity portfolio.

Second in terms of bullish sentiment is Donald Chiboucis‘ Columbus Circle Investors, which also augmented its bets on Regeneron Pharmaceuticals Inc (NASDAQ:REGN) over the last reported quarter. The fund upped its stakes by 6%, and owned more than 451,500 shares at the end of Q3, which accounted for 1% of its total equity holdings.

Finally, third in line is Ken Griffin’s Citadel Investment Group. The fund boosted its involvement in the company by 1488% in its last reported quarter. Griffin’s fund now owns 383,572 shares. Other prominent funds that also incremented their bets on Regeneron Pharmaceuticals Inc (NASDAQ:REGN) are Jim Simons’ Renaissance Technologies and Adage Capital Management.

 

Disclosure: Javier Hasse holds no position in any stocks mentioned

Recommended Reading:

General Electric Company (GE) Continues to Witness Strong Insider Activity

Irving Kahn and a Board Director Bullish About Old Republic International Corporation (ORI)

Michael Novogratz and Insiders Are Bullish About These 4 Stocks

Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Largest Pharmaceutical Companies In the World

The 10 Most Expensive Android Apps

The 9 Most Expensive Designer Bags in the World

The 7 Most Expensive Real Estate in the World

The 10 Most Expensive eBay Items Ever Sold

The 10 Most Expensive iPhone Apps

The 9 Most Expensive Designer Shoes in the World

The 10 Most Expensive Cigarette Brands

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!